|
|
Post by agedhippie on Nov 1, 2023 7:40:40 GMT -5
Thanks, that was exactly what I was looking for.
|
|
|
|
Post by cppoly on Nov 8, 2023 13:46:14 GMT -5
Maybe this question is for agedhippie, but for the hearing on December 4th with UTHR vs LQDA, is there going to be an answer that day or does it take several months for a decision? In the slight chance UTHR wins I'm assuming that's game over for LQDA?
|
|
|
|
Post by agedhippie on Nov 8, 2023 18:31:05 GMT -5
Maybe this question is for agedhippie, but for the hearing on December 4th with UTHR vs LQDA, is there going to be an answer that day or does it take several months for a decision? In the slight chance UTHR wins I'm assuming that's game over for LQDA? There could be an answer within a week, but I think the chance of that is vanishingly small. It's more likely to take two or three months, probably three given the holidays. |
|
|
|
Post by longliner on Nov 8, 2023 23:36:51 GMT -5
Maybe this question is for agedhippie, but for the hearing on December 4th with UTHR vs LQDA, is there going to be an answer that day or does it take several months for a decision? In the slight chance UTHR wins I'm assuming that's game over for LQDA? He must have missed the question. Yes |
|
|
|
Post by agedhippie on Nov 9, 2023 9:25:04 GMT -5
Maybe this question is for agedhippie, but for the hearing on December 4th with UTHR vs LQDA, is there going to be an answer that day or does it take several months for a decision? In the slight chance UTHR wins I'm assuming that's game over for LQDA? He must have missed the question. Yes Yes, I missed it and you are correct. Would it be game over for LQDA? Mostly. It would force them to pivot away from Yutrepia for the remaining term of the patent, so three years, and to focus on their other drugs. They may abandon Yutrepia entirely in that case, but my suspicion is not - it's a sunk cost and they may as well launch even if they only get a fraction of the market as it will recover some costs. |
|
|
|
Post by ptass on Nov 9, 2023 11:32:30 GMT -5
Does anyone know what happened with the lawsuit involving a former UTHR employee and the alleged theft of trade secrets?
|
|
|
|
Post by agedhippie on Nov 9, 2023 18:20:37 GMT -5
Does anyone know what happened with the lawsuit involving a former UTHR employee and the alleged theft of trade secrets? It's still out there. It doesn't have any impact on Tyvaso-DPI/Yutrepia so there is not a lot of attention. My suspicion is that it gets settled before it goes to court. |
|
|
|
Post by ptass on Nov 9, 2023 20:08:05 GMT -5
Does anyone know what happened with the lawsuit involving a former UTHR employee and the alleged theft of trade secrets? It's still out there. It doesn't have any impact on Tyvaso-DPI/Yutrepia so there is not a lot of attention. My suspicion is that it gets settled before it goes to court. Thanks. |
|
|
|
Post by harryx1 on Nov 15, 2023 12:24:58 GMT -5
|
|
|
|
Post by hellodolly on Nov 15, 2023 13:02:29 GMT -5
We're going to be revisiting this chart for a while in future discussions. The difference between DPI and Yutrepia looks like it involves the uptake and subsequent exchange in the lungs using high flow vs low fly delivery. I'm curious if the Liquidia people can explain if the large deposits of Yutrepia into the oropharnyx, instead of the lungs where the transfer of O2 and blood (I suspect also where the DPI and Yutrepia exchange occurs) in the alveoli, does it lose it's effectiveness? Or, can this be offset by loading the Liquidia device with more product to off-set the loss? Sorry if the biological and physiological descriptions are off.
|
|
|
|
Post by longliner on Nov 15, 2023 13:15:25 GMT -5
Me thinks liqidiots have been telling fibs.....
|
|
|
|
Post by hellodolly on Nov 15, 2023 13:35:32 GMT -5
Me thinks liqidiots have been telling fibs..... Another advantage to low flow vs high flow, that Mike has been saying for sometime: [paraphrase} DPI doesn't require high .mcg dosages because of the dynamics low flow has over high flow...less dose, less toxicity, equal or better outcomes. |
|
|
|
Post by agedhippie on Nov 15, 2023 18:31:52 GMT -5
Another advantage to low flow vs high flow, that Mike has been saying for sometime: [paraphrase} DPI doesn't require high .mcg dosages because of the dynamics low flow has over high flow...less dose, less toxicity, equal or better outcomes. There is no evidence of toxicity (this has been through all three phases of FDA trials). The API quantity argument is the same one that LFD has been used against Afrezza in the past and has the same flaw, it goes Afrezza takes more insulin than RAA to get the same effect so therefore Afrezza is bad. That is flatly wrong since what matters is the outcome and not the quantity of API used as Afrezza shows. Liquidia print specifically sized and shaped particles to act as carriers so they get deep lung reach via that route rather than the inhaler. In some ways Liquidia is not unlike Mannkind in that with Print they have come up with a carrier mechanism to deliver drugs deep into the lung. Their first drug is Tyvaso though rather than insulin. |
|
|
|
Post by sayhey24 on Nov 15, 2023 19:47:32 GMT -5
Another advantage to low flow vs high flow, that Mike has been saying for sometime: [paraphrase} DPI doesn't require high .mcg dosages because of the dynamics low flow has over high flow...less dose, less toxicity, equal or better outcomes. There is no evidence of toxicity (this has been through all three phases of FDA trials). The API quantity argument is the same one that LFD has been used against Afrezza in the past and has the same flaw, it goes Afrezza takes more insulin than RAA to get the same effect so therefore Afrezza is bad. That is flatly wrong since what matters is the outcome and not the quantity of API used as Afrezza shows. Liquidia print specifically sized and shaped particles to act as carriers so they get deep lung reach via that route rather than the inhaler. In some ways Liquidia is not unlike Mannkind in that with Print they have come up with a carrier mechanism to deliver drugs deep into the lung. Their first drug is Tyvaso though rather than insulin. From what I have seen TS is a better platform. Worst case is "Print" is no better but probably not and I am still waiting to see how it scales. Maybe it will but the jury is still out on that. When it comes to LFD, don't make me laugh. LFD wrote article after article about how MNKD was going bankrupt. I am as sure about that as I am about how you told us afrezza over time would case serious lung issues. |
|
|
|
Post by longliner on Nov 16, 2023 4:25:04 GMT -5
I'm curious, when Mannkind launches their next product, either alone or in partnership, will the same party here that has soft bashed both Afrezza and Tyvaso
attempt to undermine that product as well? If so, at some point you have to ask why? Why argue against our science in support of our competition?
Why (for years) undermine every attempt at success for Mannkind and it's investors?
You admittedly are not an investor in Mannkind, or an end user of our products? To what end?
It used to be your interest in diabetes, did you suddenly contract PAH as well?
As a MNKD investor it is certainly frustrating, so mission accomplished I suppose.
It's a moderated board, as long as they appreciate the content so be it.
|
|
